Overview

Fenofibrate in Ulcerative Colitis

Status:
Recruiting
Trial end date:
2025-06-20
Target enrollment:
Participant gender:
Summary
Fibrates, which are specific pharmacological agonists of PPARα, have been widely used in the treatment of hypercholesterolemia and hypertriglyceridemia. Apart from their metabolic action, anti-inflammatory properties of fibrates have been described, including inhibition of NF-kappa B signaling and pro-inflammatory cytokine production. 4 Fenofibrate, an important peroxisome proliferator-activated receptor-a (PPAR- α) agonist, is widely used in clinical as a triglyceride (TG)-lowering agent.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Tanta University
Collaborators:
Eman Ibrahim Elberri, Clinical Pharmacy Department, Faculty of Pharmacy, Tanta University
Eman Maamoun Ali El-Khateeb, Lecturer of Clinical Pharmacy, Clinical Pharmacy Department, Faculty of Pharmacy, Tanta University
Hend El-Said Abo Mansour, Biochemistry Department, Faculty of Pharmacy, Menoufia University
Monir Hussein Bahgat, Internal Medicine Department (Gastroenterology and Hepatology), Faculty of Medicine, Mansura University
Treatments:
Fenofibrate
Mesalamine